Charles River Laboratories International (CRL)

Ticker: CRL Earnings Date: August 5, 2026 (Pre-Market) Reporting Period: Q2 2026 Prepared: August 4, 2026

1. Earnings Preview

Key Takeaway: Setup is modestly constructive — consensus is a manageable bar with EPS of ~$2.75 and revenue of ~$980M, and the single biggest swing factor is whether the promised sequential margin recovery (≥30% EPS step-up guided by management) materializes as discrete Q1 headwinds (NHP sourcing costs, CEO transition stock comp, NHP shipment timing) fully subside.

Heading into Q2 2026 results, the bar looks achievable but not easy: consensus sits at $979.9M in revenue (organic decline of ~1.7%) and $2.75 in adjusted EPS — a sequential jump of ~34% from Q1's $2.06, which management explicitly guided to at least 30% improvement. Management's posture on the Q1 call was notably more confident, reaffirming full-year organic revenue guidance of -0.5% to -1.5% and EPS of $10.80–$11.30, and providing a clear bridge to H2 margin expansion of over 500 bps vs. H1 — driven by the CDMO divestiture (closed May 6), European discovery site divestiture (closed May 22), and KF Cambodia NHP farm normalization. Estimate revisions since the Q1 print have been essentially flat (FY EPS consensus moved from $11.06 to $11.08), suggesting the street is tracking guidance rather than getting ahead of it, which limits downside risk from a revision-driven de-rating. The stock has surged +28.9% since the Q1 earnings date (vs. XBI +13.6%, SPY +5.4%), pricing in a meaningful portion of the recovery narrative, so the stock needs the Q2 print to confirm the margin inflection story — any shortfall on operating margin or a book-to-bill slipping below 1.0x would be the key downside risk. The wildcard is DSA book-to-bill: holding above 1.0x for a third consecutive quarter would validate management's cautious optimism on a full-year average above 1.0x and support the H2 DSA organic growth recovery thesis; a slip below 1.0x would reignite demand recovery skepticism despite the margin story.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable but not low bar — the EPS estimate of $2.75 requires the guided sequential margin recovery to fully materialize, making adjusted EPS the bigger swing factor given the wide Q1-to-Q2 step-up implied; revenue consensus at ~$980M is broadly in line with management's low-single-digit organic decline guidance.

Table 1 — Q2 2026 Current Quarter Snapshot

Source: Visible Alpha consensus data. All consensus figures as of August 4, 2026. YoY change calculated vs. Q2 2025 actuals. Reported revenue decline is larger than organic due to ~500 bps headwind from divestitures (CDMO, Cell Solutions, European Discovery sites).

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs: Total Revenue & Adjusted EPS)

Pattern: CRL has beaten adjusted EPS consensus in 7 of the last 8 quarters (only Q2 2024 revenue was a marginal miss), with an average EPS beat of ~+9% — the street has consistently set a beatable bar, though the Q2 2025 EPS beat of +24.9% was an outlier driven by discrete items. Source: Visible Alpha.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance has been reaffirmed twice since Q1 earnings (at Q1 print on May 7 and again on June 2), with no changes to organic revenue or EPS ranges — management's tone is cautiously confident, emphasizing the H2 margin inflection story and the Investor Day in September 2026 as the next major catalyst for long-term target disclosure.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been essentially flat since the Q1 print — FY 2026 EPS consensus moved only +0.2% and revenue was unchanged, suggesting the street is tracking guidance rather than getting ahead of it. The Q2 EPS estimate of $2.75 sits just above the guided floor of $2.68 (≥30% sequential increase), leaving a narrow but real cushion for a beat if the margin recovery is even slightly better than expected.

Estimates have been remarkably stable since the Q1 print, with virtually no revision activity — the street is in a holding pattern, waiting for Q2 results to confirm the margin inflection before making material estimate changes. The FY 2027 EPS estimate of $12.28 implies ~10.8% growth over FY 2026 consensus, which is consistent with management's directional commentary but lacks specific long-term targets (to be provided at September 2026 Investor Day). Source: Visible Alpha.

5. Stock Performance

Key Takeaway: CRL has dramatically outperformed since Q1 earnings, up +28.9% vs. XBI +13.6% and SPY +5.4% — the outperformance is driven by a combination of multiple re-rating on the demand recovery narrative and the concrete margin inflection story from divestitures, with the stock now trading at ~$234 vs. the Q1 earnings day close of $181.68; the stock needs the Q2 print to validate the re-rating.

CRL vs. XBI (Biotech ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings Date (May 7, 2026). Source: Yahoo Finance.

Sector ETF used: XBI (SPDR S&P Biotech ETF) — appropriate for CRL given its primary exposure to biotech/biopharma R&D spending cycles and the biotech funding environment as a key demand driver. CRL's +28.9% gain since Q1 earnings compares to XBI's +13.6% and SPY's +5.4%, representing meaningful alpha generation. The stock's sharp rally from ~$150 in mid-May to ~$234 today was driven by: (1) the ICLR Q1 earnings on May 28 showing strong CRO demand read-through; (2) the June 2 guidance reaffirmation; and (3) a series of analyst price target upgrades (Morgan Stanley to $260, Mizuho to $230, Bernstein and BNP Paribas to $250) in late June/July. The stock is now trading at a premium to its recent range, making the Q2 print a critical validation event.

6. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Peer commentary from IQVIA (Q2 2026 earnings, July 28), ICON (Q2 2026 earnings, July 30), and Medpace (Q2 2026 earnings, July 22) is broadly constructive for CRL's Q2 print — biotech funding hit a record $35B in Q2 (IQVIA), CRO demand metrics are accelerating across all client segments, and the drug development pipeline is increasingly skewing toward later-stage (Phase III) programs that feed directly into CRL's safety assessment business. The read-through is most positive for DSA book-to-bill and biotech demand, and less directly relevant for CRL's manufacturing or RMS segments.

IQVIA (IQV) — Q2 2026 Earnings (Reported July 28, 2026)

• Biotech funding hit a record $35B in Q2 2026 (per Bioworld), more than double Q2 2025 levels — the strongest read-through for CRL's biotech client demand recovery. IQVIA noted it typically takes 9–15 months for EBP funding to translate into contracted bookings, suggesting the full tailwind from recent record funding quarters has not yet been realized in CRL's revenue.
• CRO demand metrics accelerating: IQVIA reported RFP flow growth of double digits both year-over-year and sequentially, with improvement across all client segments. Decision timelines are shortening. IQVIA's R&D Solutions net new bookings were $3.15B in Q2, up 19.3% YoY, with a book-to-bill of 1.22x — the third consecutive quarter of industry-leading book-to-bills. This is a strong positive read-through for CRL's DSA bookings.
• AI as a tailwind, not a headwind: IQVIA's CEO stated that large pharma clients are telling them to 'gear up capacity' as AI-driven drug discovery is expected to double study portfolios. This directly supports CRL's thesis that AI will increase, not decrease, demand for preclinical safety assessment services.
• Large pharma pipeline reprioritization largely complete: IQVIA noted that programs of reprioritization and pipeline cleansing are 'mostly complete' for large pharma, with leading indicators (RFP flow, qualified pipeline) up mid-to-high single digits. This is consistent with CRL's Q1 commentary that global biopharma clients have progressed through restructuring.
• IQVIA completed acquisition of CRL's European discovery assets in Q2 2026, adding ~$75–80M to IQVIA's revenue — confirming the divestiture closed as planned and the proceeds/EPS accretion should flow through CRL's Q2 results.
• Full-year 2026 guidance raised: IQVIA raised FY 2026 revenue guidance to $17.275–17.475B (midpoint +0.7% vs. prior), citing ~100 bps higher organic revenue growth and ~50 bps higher M&A contribution. A CRO industry leader raising guidance is a positive macro read-through for the broader preclinical/clinical services demand environment.

ICON (ICLR) — Q1 2026 Earnings (Reported May 28, 2026)

• Biotech funding 'remained generally positive' with ongoing activity in larger follow-on capital raises supporting late-stage clinical programs. ICON's CEO noted 'biotech funding remains constructive' — consistent with CRL's Q1 commentary on mid-sized and mature biotech demand improving.
• Strong bookings: ICON Q1 gross bookings were $3.3B, matching Q4 2025's strong performance and up 22% YoY. Net book-to-bill was 1.42x (direct fee 1.3x). RFP flow increased low double digits sequentially in the biotech full-service business. Win rates remained strong in both large pharma and biotech. This is a strong positive read-through for CRL's DSA demand environment.
• Phase III skew increasing: ICON noted the number of Phase III trials in Q2 awards was up ~38–39%, with average skews from 29 to 45 in Q2. More Phase III activity means more molecules progressing through development, which is a leading indicator for CRL's safety assessment demand.
• Mid-sized pharma opportunity flow improving up high teens YoY, with several strategic partnership discussions underway — consistent with CRL's commentary on mid-sized biotech demand recovery.
• Q2 2026 outlook: ICON guided to Q2 EBITDA margin of ~16%, with 'Q2 looking like a very strong quarter for signing' and biotech RFP flow expected to see 'very significant increases.' This forward-looking commentary is a positive read-through for CRL's Q2 DSA bookings.

ICON (ICLR) — Q2 2026 Earnings (Reported July 30, 2026)

• Marked increase in biotech RFP flow in Q2 2026: ICON reported a 'notable uptick in biotech demand' with RFP flow up 22% sequentially and 16% on a trailing 12-month basis. Midsized and biotech companies represented 8 of ICON's top 10 customers by awards in Q2 — a strong positive read-through for CRL's biotech client segment.
• Phase III proportion rising to ~50% of total opportunity volume in Q2 vs. ~40% a year ago, indicating customers are 'increasingly bringing assets into the later phases of development.' This is a direct positive read-through for CRL's DSA safety assessment pipeline, as Phase III programs require extensive preclinical and safety work.
• Net book-to-bill of 1.51x (direct fee 1.2x) in Q2 2026 — ICON's third consecutive quarter of industry-leading book-to-bills. The direct fee book-to-bill averaged ~1.25x for H1 2026. This sustained above-1.0x bookings environment is a strong positive read-through for CRL's DSA book-to-bill.
• Cardiometabolic research ticking up in biotech — ICON noted cardiometabolic is 'broadly comparable' to oncology in recent opportunity flow and awards, with the proportion of cardiometabolic research increasing in biotech. This therapeutic mix shift (obesity, MASH, kidney disease) is a positive for CRL as these are complex, multi-study programs.
• Overall demand environment 'remains generally constructive' despite expected seasonal impact over summer months. ICON reaffirmed full-year 2026 guidance, with the underlying direct fee decline of ~2% organically — a more cautious data point, but ICON's revenue mix (clinical CRO) is different from CRL's (preclinical/safety assessment).

Medpace (MEDP) — Q2 2026 Earnings (Reported July 22, 2026)

• Strong Q2 2026 results: Medpace reported Q2 revenue of $707.3M, up 17.2% YoY, with a net book-to-bill of 1.13x and backlog of $3.01B (up 4.9% YoY). EBITDA margin was 21.7%. This is a strong positive read-through for the broader CRO demand environment, particularly for biotech-focused CROs.
• Full-year 2026 guidance raised to $2.805–$2.885B (10.9%–14.0% growth over 2025), with EBITDA of $618–$642M. Medpace is the most biotech-focused of the major CROs, so its strong guidance raise is a particularly relevant positive read-through for CRL's biotech client demand.
• Backlog conversion rate of 24.1% in Q2 2026 — a high conversion rate indicating strong execution and healthy demand. Net new business awards of $795.7M were up 28.2% YoY, the strongest bookings growth among peers. This reinforces the biotech demand recovery narrative that underpins CRL's H2 DSA organic growth return thesis.

IQVIA — Jefferies Conference (June 3, 2026) & BofA Conference (May 13, 2026)

• April 2026 EBP funding was triple April 2025 levels (Jefferies Conference, June 3) — IQVIA's CEO noted 'April funding was triple what it was last year's April,' with Q1 2026 EBP funding also 'very, very strong.' This is a strong positive read-through for CRL's biotech demand pipeline, as funding typically leads bookings by 9–15 months.
• Q1 2026 EBP funding was 'almost double' Q1 2025 levels (BofA Conference, May 13) — IQVIA CFO noted Q1 funding was 'almost double what it was last year' and BioWorld April funding was 'up almost 400% versus April in '25.' This is the most bullish biotech funding data point in the peer commentary set.
• Large pharma R&D spend stable, pipeline reprioritization largely complete — IQVIA described large pharma as 'stable' with 'still some sand in the gears' from policy-related actions, but programs of reprioritization are 'largely behind us.' This is consistent with CRL's Q1 commentary and supports the thesis that pharma demand headwinds are fading.
• AI in discovery expected to increase CRO demand: IQVIA's CEO stated that 'the bottleneck in drug development is clinical trials, not discovery' and that AI will 'identify more molecules that are more likely to succeed in trial,' driving more demand for CRO services. This directly supports CRL's AI-as-tailwind thesis for safety assessment.

Summary Read-Through Assessment: The peer commentary set is uniformly positive for CRL's Q2 DSA demand environment. Record biotech funding ($35B in Q2 per IQVIA), accelerating RFP flow across all client segments, rising Phase III activity, and strong book-to-bills at ICON and Medpace all point to a healthy demand backdrop for CRL's safety assessment business. The read-through is less directly relevant for CRL's RMS and Manufacturing segments, which are driven by different dynamics (NHP supply, biologics testing). The key risk is that CRL's preclinical safety assessment demand lags clinical CRO demand by 1–2 quarters, so the strong clinical bookings at ICON and IQVIA may not yet be fully reflected in CRL's Q2 DSA revenue.

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the completion of the CDMO/Cell Solutions and European Discovery site divestitures — these are the primary drivers of the guided H2 margin inflection and their successful close removes execution risk from the Q2 margin recovery story.

• May 6, 2026 — CDMO & Cell Solutions Divestiture Closed: CRL closed the sale of its CDMO and Cell Solutions businesses. This is the single most important margin catalyst for 2026, as the divested businesses were dilutive to consolidated margins. Management guided that the Manufacturing segment operating margin should return to historical levels above 30% as early as Q2 2026, with the divestiture expected to contribute over half of the guided H2 margin improvement of >500 bps vs. H1.
• May 22, 2026 — European Discovery Sites Divestiture Closed: CRL closed the sale of five European discovery sites (Cambridge UK, Freiburg Germany, Kuopio Finland, Portishead UK, Leiden Netherlands). IQVIA confirmed at its Q2 2026 earnings call (July 28) that it completed the acquisition of these 'Charles River assets' in Q2, adding ~$75–80M to IQVIA's revenue. This removes another margin headwind and allows CRL to refocus on core regulated preclinical services.
• May 11, 2026 — Shareholders Approve New Incentive Plan: CRL shareholders approved a new equity incentive plan and elected directors at the annual meeting. Routine governance event; no material financial impact.
• June 1–2, 2026 — William Blair & Jefferies Conference Presentations; Guidance Reaffirmed: CRL presented at the William Blair and Jefferies healthcare conferences. On June 2, management reaffirmed full-year 2026 organic revenue and EPS guidance, consistent with the Q1 earnings reaffirmation. This was the second post-Q1 guidance reaffirmation, reinforcing management's confidence in the full-year outlook.
• July 1, 2026 — Analyst Price Target Actions: Sanford C. Bernstein set a $250 price target and BNP Paribas Exane set a $250 price target on CRL. These were among the most bullish PT actions since Q1 earnings, reflecting growing confidence in the margin recovery story.
• July 13, 2026 — Mizuho Raises Price Target to $230: Mizuho analyst Ann Hynes maintained a Neutral rating but raised the price target from $192 to $230, citing improving demand fundamentals and the margin inflection story.
• July 15, 2026 — Q2 2026 Earnings Date Announced: CRL announced Q2 2026 results will be released before market open on August 5, 2026, with a conference call at 9:00 AM ET. Routine scheduling announcement.
• July 20, 2026 — CLSA Downgrade to Hold: CLSA analyst Michael Luo downgraded CRL from Outperform to Hold, maintaining a $219 price target. The downgrade likely reflects the stock's significant run-up (+28.9% since Q1 earnings) and the view that the recovery is now priced in at current levels. This is a notable cautionary signal heading into the print.
• Morgan Stanley Upgrade to Overweight, PT Raised to $260: Morgan Stanley analyst Ricky Goldwasser upgraded CRL from Equal-Weight to Overweight and raised the price target from $185 to $220 (subsequently raised further to $260). This was one of the most significant analyst actions since Q1 earnings, reflecting conviction in the demand recovery and margin inflection thesis.
• Analyst Consensus: As of August 4, 2026, 11 Buy ratings, 4 Hold ratings, 1 Sell rating; average price target of $220.75 (below current price of $234.12). The stock has run through the average PT, suggesting the market is pricing in a successful Q2 print.
• Macro/Industry: Biotech funding environment remains highly constructive — IQVIA reported Q2 2026 EBP funding of $35B (more than double Q2 2025). NIH/government funding pressure remains a modest headwind for CRL's academic and government client segment, but revenue from this segment was stable in Q1 2026. Biopharma M&A activity remains elevated, providing additional capital for biotech clients.

8. Insider Transaction Activity

Key Takeaway: The only insider transaction since Q1 earnings is a large planned sale by former CEO James C. Foster (75,000 shares, ~$16.9M) executed under a 10b5-1 plan — this is a pre-planned, obligation-driven transaction by a departing executive and carries no negative signal for the business outlook; no open-market discretionary buys or sells were filed by current management.

Source: SEC Form 4 filing, filed July 1, 2026. No open-market discretionary buys or sells were filed by current management (CEO Birgit Girshick, CFO Glenn Coleman, or other current officers) since Q1 earnings. The absence of insider buying by new management is notable but not unusual given the CEO and CFO are both newly appointed (May 2026 and April 2026, respectively) and likely subject to trading blackout periods and onboarding restrictions. The Foster sale is entirely consistent with a departing executive monetizing equity under a pre-established plan and should not be read as a negative signal.